Gerald Brunk Acquires 31,000 Shares of enGene Therapeutics
On June 16, 2026, Gerald Brunk purchased 31,000 shares of enGene Therapeutics.
Key Points
- Gerald Brunk bought 31,000 shares of enGene Therapeutics on June 16, 2026.
- Shares of enGene Therapeutics traded near $1.75 with a market cap of about $117.2 million.
- The biotechnology company specializes in genetic medicines for bladder cancer and is headquartered in Montreal, Canada.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, Gerald Brunk purchased 31,000 shares of enGene Therapeutics Inc. (NasdaqCM:ENGN). This insider transaction was not part of a pre-planned trading program.
enGene Therapeutics Inc. Stock Down 4.7%
Shares of enGene Therapeutics traded near $1.75. The company's market cap stands at approximately $117.2 million. enGene is not currently profitable, so it has no meaningful P/E ratio. The stock has seen a 52-week low of $1.40 and a high of $12.25, with a 50-day moving average of $4.33 and a 200-day moving average of $7.13. The firm maintains a strong liquidity position with a current ratio of 12.57 and a quick ratio of 12.07, although it has a debt-to-equity ratio of 13.07.
About enGene Therapeutics
enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada. The company focuses on developing genetic medicines aimed at treating bladder cancer. Its lead product candidate, detalimogene voraplasmid, is a monotherapy for non-muscle invasive bladder cancer. The company also has a pipeline project called LEGEND, which is in Phase 2. enGene Therapeutics is led by CEO Ronald H. W. Cooper and employs 81 people.
Bottom Line
Gerald Brunk's recent purchase of enGene Therapeutics shares highlights ongoing insider interest in the company. Investors often watch insider transactions for insights into company prospects, though it's important to remember that such trades don't always predict stock performance. enGene Therapeutics continues to focus on its genetic medicine pipeline, offering potential growth in the healthcare sector.
Get enGene Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $ENGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.